TY - JOUR
T1 - VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain
AU - Marzi, Andrea
AU - Robertson, Shelly J.
AU - Haddock, Elaine
AU - Feldmann, Friederike
AU - Hanley, Patrick W.
AU - Scott, Dana P.
AU - Strong, James E.
AU - Kobinger, Gary
AU - Best, Sonja M.
AU - Feldmann, Heinz
N1 - Publisher Copyright:
© 2015, American Association for the Advancement of Science. All rights reserved.
PY - 2015/8/14
Y1 - 2015/8/14
N2 - The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.
AB - The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and Liberia, creating a global public health crisis and accelerating the assessment of experimental therapeutics and vaccines in clinical trials. One of those vaccines is based on recombinant vesicular stomatitis virus expressing the EBOV glycoprotein (VSV-EBOV), a live-attenuated vector with marked preclinical efficacy. Here, we provide the preclinical proof that VSV-EBOV completely protects macaques against lethal challenge with the West African EBOV-Makona strain. Complete and partial protection was achieved with a single dose given as late as 7 and 3 days before challenge, respectively. This indicates that VSV-EBOV may protect humans against EBOV infections in West Africa with relatively short time to immunity, promoting its use for immediate public health responses.
UR - http://www.scopus.com/inward/record.url?scp=84940172223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940172223&partnerID=8YFLogxK
U2 - 10.1126/science.aab3920
DO - 10.1126/science.aab3920
M3 - Article
C2 - 26249231
AN - SCOPUS:84940172223
SN - 0036-8075
VL - 349
SP - 739
EP - 742
JO - Science
JF - Science
IS - 6249
ER -